Evidence map›Paper›PMID 23201598›Full record

ReviewCancer letters2013

Nanoformulation of natural products for prevention and therapy of prostate cancer.

Vanna Sanna, Imtiaz A Siddiqui, Mario Sechi, Hasan Mukhtar

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Topical Delivery ofPharmacognosy magazine · 2017
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Vanna SannaDepartment of Dermatology, University of Wisconsin, Madison, WI, USA; Department of Chemistry and Pharmacy, Laboratory of Nanomedicine, University of Sassari, Italy.
Imtiaz A SiddiquiDepartment of Dermatology, University of Wisconsin, Madison, WI, USA.
Mario SechiDepartment of Dermatology, University of Wisconsin, Madison, WI, USA; Department of Chemistry and Pharmacy, Laboratory of Nanomedicine, University of Sassari, Italy.
Hasan MukhtarDepartment of Dermatology, University of Wisconsin, Madison, WI, USA. Electronic address: hmukhtar@wisc.edu.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Investigative Dermatology Training Program at University of Wisconsin-MadisonT32AR055893 · NIAMS · UNIVERSITY OF WISCONSIN-MADISON · PI MUKHTAR, HASAN · 2009 to 2013
$984k
NCI NIH HHS P30 CA014520NIAMS NIH HHS T32 AR055893NIAMS NIH HHS T32AR055893
6 · The paper itself

Abstract

There is a need for developing improved therapeutic options for the management of prostate cancer, able to inhibit proliferation of precancerous and malignant lesions and/or to improve the effectiveness of conventional chemopreventive and chemotherapeutic agents. In this perspective, application of nanotechnology based strategies for the delivery of natural compounds for effective management of the disease is being actively researched. Here, after highlighting the most promising natural compounds for chemoprevention and chemotherapy of prostate cancer, the state of the art nanotherapeutics and the recent proof-of-concept of "nanochemoprevention", as well as the clinical development of promising targeted nanoprototypes for use in the prostate cancer treatment are being discussed.

Indexed as

AnimalsAnticarcinogenic AgentsAntigens, SurfaceAntineoplastic AgentsBiological ProductsDocetaxelGlutamate Carboxypeptidase IIHumansMaleMolecular Targeted TherapyNanoparticlesNanotechnologyProstatic NeoplasmsTaxoidsAnticarcinogenic AgentsAntigens, SurfaceAntineoplastic AgentsBiological ProductsDocetaxelFOLH1 protein, humanGlutamate Carboxypeptidase IITaxoids

Identifiers

PMID23201598
PMCPMC3890375

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.